ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback